Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

MORPHOSYS : AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25/2011 | 07:35am CEST

MorphoSys AG / AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its AbD Serotec unit entered a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. Dana-Farber is engaged in research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, to develop transient immunity against life-threatening viral infections. AbD Serotec will provide the laboratory of Wayne Marasco, MD, PhD with research tools using its proprietary Slonomics technology platform. AbD Serotec will receive financial compensation and has preferred access to commercialization rights for products generated during the collaboration.

"We are delighted to provide a world-class research organization with innovative research tools. This alliance can lead to both short- and long-term value for AbD Serotec and the entire MorphoSys group in the infectious disease area," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.



About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:



HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and Slonomics® are registered trademarks of MorphoSys; arYlaTM is a trademark of MorphoSys.



This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.




For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122


Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454


Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332


[email protected]:
mailto:[email protected]


Press Release:

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MORPHOSYS AG
05:25pMORPHOSYS AG : Release according to Article 41 of the WpHG [the German Securitie..
10:33aMORPHOSYS : Resolves a Capital Increase to Implement the Offering of 8,300,000 A..
04/20MORPHOSYS : Cancer biotech MorphoSys prices $208 million US offering at $25.04
04/19MORPHOSYS : raises $208M in NASDAQ listing
04/18MORPHOSYS : Announces Pricing of Initial Public Offering of American Depositary ..
04/18MORPHOSYS : Announces Pricing of Initial Public Offering of American Depositary ..
04/18AD HOC : MorphoSys Resolves a Capital Increase to Implement the Offering of 8,30..
04/18MORPHOSYS : Resolves a Capital Increase to Implement the Offering of 8,300,000 A..
04/18MORPHOSYS : Resolves a Capital Increase to Implement the Offering of 8,300,000 A..
04/13CELGENE : MorphoSys Nominates New Candidates for Supervisory Board
More news
News from SeekingAlpha
04/19MorphoSys prices IPO at $25.04 per ADS, trading commences today 
04/14SA STOCK TO WATCH : Netflix To The Rescue? 
04/07U.S. IPO WEEK AHEAD : Subscription Unicorn Zuora Kicks Off The Q2 IPO Market 
03/183 THINGS IN BIOTECH, MARCH 17 : Janssen's Bladder Breakthrough, MorphoSys' Alzhe.. 
03/13MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2017 Results - Earnings Call Trans.. 
Financials (€)
Sales 2018 32,5 M
EBIT 2018 -106 M
Net income 2018 -101 M
Finance 2018 167 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 71,9x
EV / Sales 2019 37,7x
Capitalization 2 507 M
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 87,4 €
Spread / Average Target 2,5%
EPS Revisions
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Marc Cluzel Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG11.26%3 080
CELLTRION, INC.--.--%31 467
LONZA GROUP-6.95%18 703